• About Us
  • Therapeutic Focus
  • Technology & IP
  • Pipeline
  • Commercial
  • Business Development
  • News & Media
  • Contact Us

Company Spotlight

Charleston Laboratories, Inc. Resubmits NDA for CL-108

Charleston Laboratories, Inc. Reacquires Rights to Novel Investigational Treatment CL-108,
for Acute Pain and Opioid-Induced Nausea and Vomiting

Charleston Laboratories, Inc. Announces Formation of U.S. Commercial Subsidiary

Prescription for Success

Our Story

It was in late 2005 when a seemingly simple idea hit Charleston Laboratories founder and CEO Paul Bosse like a ton of bricks.

Our Difference

From a clinical standpoint, pain is the most common and demanding symptom to treat.

Press Releases

View All

Charleston Laboratories, Inc. Resubmits NDA for CL-108

Company News

View All

Raymond A. Dionne D.D.S., Ph.D Joins Charleston Laboratories

Publications

View All

Events

View All

©  Charleston Laboratories, Inc. All Rights Reserved. Privacy Policy